PTK6 and neoplasm: Given that Bcl-xL has been linked with chemotherapeutic resistance to treatments such as doxorubicin [17], it was hypothesized that Brk expression could modulate tumour cell responses to doxorubicin and possibly other chemotherapeutic agents.